1.A Hidden Diagnosis: Disseminated Histoplasmosis Mimicking Tuberculosis in the Elderly
Wan Muhamad Amir Wan Md Zin ; Moon Yan Yap ; Meroshini Sundaran ; Siti Nabilah &lsquo ; Atiqah Othman ; Siti Nabihah Mohamed Hatta ; Maz Anirah Abdul Azis
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):28-
Introduction:
Histoplasmosis is a rare opportunistic, inhalation-acquired
systemic mycosis caused by Histoplasma capsulatum,
endemic to Southeast Asia, including Malaysia. Although
classically seen in immunocompromised hosts, it is
increasingly reported in immunocompetent individuals.
Infection is associated with environmental exposures such
as bat or bird droppings and soil disruption. Histoplasmosis
is a progressive granulomatous disease that can closely
mimic tuberculosis and malignancy, making diagnosis
challenging.
Case:
An 87-year-old Malay male with a history of treated
pulmonary tuberculosis presented with a 6-month history
of intermittent fever, anorexia, weight loss, and hypotension. Initial computed tomography imaging demonstrated bilateral heterogeneous adrenal masses (right: 2.2
× 3.7 × 5.0 cm; left: 2.0 × 3.7 × 5.2 cm) with indeterminate
washout characteristics. Biochemical adrenal evaluation,
including a short Synacthen test, confirmed primary
adrenal insufficiency. Extensive microbiological and
malignancy workup, including bronchoscopy, cultures,
and tumor markers, was non-diagnostic. In view of clinical
deterioration and epidemiological risk, empirical antituberculous therapy was initiated; however, no clinical
improvement was observed after 2 months. PET-FDG revealed intensely hypermetabolic bilateral adrenal masses
(SUVmax right 16.7, left 13.2) with no other abnormal
foci. Non-invasive fungal investigations were negative.
Definitive diagnosis was established via computed
tomography-guided adrenal biopsy, which demonstrated
necrotizing granulomatous inflammation with intracellular
yeasts, subsequently identified as H. capsulatum. The patient
was treated with oral itraconazole and corticosteroid
replacement, resulting in significant clinical improvement
and planned interval radiological reassessment.
Conclusion
Disseminated histoplasmosis is a diagnostic challenge,
particularly in frail elderly patients, where invasive
procedures may be delayed. It can mimic tuberculosis
and malignancy and may lack an identifiable exposure
history. Non-invasive tests may be inconclusive, making
tissue biopsy essential. Adrenal involvement may result
in primary adrenal insufficiency, further complicating
the clinical picture. Early consideration and timely
confirmation are crucial for appropriate management.
Adrenal incidentaloma
;
Lung Neoplasms
2.Hashimoto's Thyroiditis Presenting With Recurrent Massive Pleural Effusion Suggestive of Lymphocytic Interstitial Pneumonitis
Endah Pratamaningtias ; Nyoman Satvika Dharma Yudha
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):106-
Introduction:
Hashimoto's thyroiditis is a common autoimmune thyroid
disease; however, pulmonary involvement is a rare
manifestation. Lymphocytic interstitial pneumonitis is
commonly associated with autoimmune diseases, but its
association with Hashimoto's thyroiditis remains poorly
understood.
Case:
A 63-year-old male with prior diagnosis of Hashimoto's
thyroiditis presented with recurrent massive pleural
effusion and progressive dyspnea. He also experienced
fatigue, cold intolerance, and constipation. Physical
examination revealed facial puffiness, diffuse goiter, and
dry skin. Thyroid function tests performed 6 months before
admission confirmed overt hypothyroidism (thyroidstimulating hormone [TSH] 80.30 µIU/mL, free thyroxine
4 [FT4] 0.46 ng/dL). One month prior to admission,
laboratory findings showed subclinical hypothyroidism
(TSH 9.09 µIU/mL, FT4 1.42 ng/dL). Despite levothyroxine
treatment TSH levels remained elevated at 21.8 µIU/mL
during admission. Anti-thyroid peroxidase antibodies were
positive (13.95 IU/mL). Repeated thoracentesis revealed
exudative pleural effusion with lymphocytic predominance
and no evidence of malignancy in cytological examination.
Infectious etiologies and malignancy were ruled out.
Thyroid ultrasonography demonstrated diffuse hypoechoic
enlargement of the thyroid gland. Chest radiography
showed massive unilateral pleural effusion, while thoracic
computed tomography revealed ground-glass opacities
with a reticulogranular pattern and interlobular septal thickening, accompanied by multiple thin-walled cysts,
highly suggestive of lymphocytic interstitial pneumonitis.
Thyroid immunohistochemical analysis was performed
(CD 20, CD 3, CD 10, CD 138, Ki 67, BCL 2, BCL 6,
Thyroglobulin, MUM 1, Cyclin D1), consistent with
lymphocytic thyroiditis. Significant clinical and laboratory
improvement was achieved after combined treatment with
levothyroxine and corticosteroid.
Conclusion
This case underscores the importance of considering
autoimmune-related lymphocytic interstitial pneumonitis
in patients with Hashimoto's thyroiditis who present with
unexplained recurrent pleural effusion after exclusion of
more common etiologies, such as infection and malignancy.
Early recognition may lead to favorable improvement.
Lung Diseases, Interstitial
;
Pleural Effusion
;
Thyroiditis
3.Comparative copy number variation profiling of GL01, an immortalized non-small cell lung cancer cell line derived from a Filipino patient, and A549 lung adenocarcinoma cells
Treena Rica D. Teh ; Kim Claudette J. Fernandez ; Maria Katrina Diana M. Cruz ; Patrick Gabriel G. Moreno ; Ruel C. Nacario ; Gladys C. Completo ; Francisco M. Heralde III
Acta Medica Philippina 2025;59(10):37-51
BACKGROUND AND OBJECTIVES
Cell lines serve as invaluable tools in studying lung cancer biology and developing new therapies to combat the disease. However, commercially available cell lines are typically of Caucasian origin and may be less representative of the local genetic background. To address this, our lab previously immortalized cells from pleural fluid of a Filipino non-small cell lung cancer (NSCLC) patient via CDK4 transduction. Copy number variations (CNVs) are a type of genetic variation which may affect physiology and disease by disrupting gene function or altering gene expression, and in cancer, these may be associated with patient outcomes. CNV profiling can be valuable for understanding the biology of our immortalized cells and identifying genes that could serve as potential targets for diagnostic, prognostic, and therapeutic interventions. This study aimed to characterize previously immortalized NSCLC-derived cells, GL01, in comparison with an established lung adenocarcinoma (LUAD) cell line, A549, through whole-genome microarray-based copy number profiling.
METHODSDNA was extracted from GL01 and A549 cells using a commercially-available silica-based DNA extraction kit. DNA extracts were quantified and normalized for microarray analysis. Whole-genome copy number profiling was done using the OncoScan CNV Plus Assay following the manufacturer’s protocols, and data was analyzed using the Chromosome Analysis Suite software. Functional analysis of genes identified to be involved in copy number aberrations was done using the PANTHER Classification System.
RESULTSCopy number aberrations span 1,592,737,105 bp in GL01 and 1,715,708,552 bp in A549, with a high degree of concordance between the two. Large-scale and focal copy number aberrations previously identified to be recurrent in various LUAD cohorts were present in both GL01 and A549. Focal copy number aberrations associated with previously described lung cancer-related genes involve the PDE4D gene in GL01 and the SKIL and CDKN2A/CDKN2B genes in both GL01 and A549. PANTHER Pathway analysis of genes positively correlated with mRNA expression showed that the ubiquitin proteasome pathway was significantly overrepresented in both GL01 (FDR p = 0.000074) and A549 (FDR p = 0.000075), with 20 genes involved. Additionally, the KRAS:p.G12C/S:c.34G>T/A somatic mutation variant was detected in both GL01 and A549.
CONCLUSIONThis study provides a method for identifying potentially clinically-relevant genes associated with a sample’s copy number aberrations and the pathways they represent, providing personalized mechanistic, prognostic, and therapeutic insights into the cancer biology of our cells.
Human ; Carcinoma, Non-small-cell Lung ; Adenocarcinoma Of Lung
4.Clinical profile and outcomes of all admitted COVID-19 positive patients with primary lung cancer in a Tertiary Government COVID-19 Referral Center: A retrospective cohort study
Ria Katrina B. Cortez ; Joel M. Santiaguel ; Mary Bianca Doreen F. Ditching
Acta Medica Philippina 2025;59(11):75-86
BACKGROUND
COVID-19 infection poses a continuing challenge especially to those already with prior lung disease. To analyze such patients’ profile is essential in today’s health care management.
OBJECTIVEThe study aimed to compare the outcomes of COVID-19 confirmed patients with and without primary lung cancer in terms of hospital stay, recovery, and mortality.
METHODSThe study employed a retrospective cohort design. Chart review of all adult COVID-19 patients in Philippine General Hospital from January 2021 to June 2021 was done. A matched cohort study was conducted between COVID-19 patients with and without primary lung cancer.
RESULTSAmong the 953 COVID-19 patients, there were 14 patients with primary lung cancer. In terms of length of hospital stay, patients with primary lung cancer had shorter days from 1.32 to 15.1 days compared to 2.28 to 18.36 days in patients without primary lung cancer (p-value 0.271). Furthermore, they had 64% recovery rate compared to 78% in those without primary lung cancer (p-value 0.118). In terms of overall mortality rate, primary lung cancer patients had 36% rate as compared to 22% in the non-lung cancer group (p-value 0.119). Diabetes mellitus, mild to severe COVID, Remdesivir, and antibiotic use were associated with longer hospital stay while oxygen support via nasal cannula and invasive ventilation led to shorter hospital stay. Age above 50 years, chronic liver disease, other malignancy, shortness of breath, oxygen support via face mask, high flow nasal cannula, invasive ventilation, antibiotic use, hemoperfusion and nebulization showed a decrease chance of recovery while on contrary, Remdesivir showed an increase chance of recovery. An increase mortality rate was seen among age above 50 years, chronic liver disease, other malignancy, shortness of breath, oxygen support via facemask, high flow nasal cannula, invasive ventilation, antibiotics, hemoperfusion, and nebulization, in contrast to a decrease in Remdesivir therapy.
CONCLUSIONSAmong all admitted COVID-19 patients, primary lung cancer patients were associated with shorter hospital stay (8.21+6.89days), lower rate of recovery (64%), and higher mortality rate (36%) as compared to those without primary lung cancer. However, based on the computed p-values for each outcome, these differences are not statistically significant.
Covid-19 ; Lung Cancer ; Lung Neoplasms
5.Malignant cardiac tamponade: A case report on rare initial presentation of non-small cell lung adenocarcinoma in a 59-year-old Filipino smoker
Maria Karina Pe ; Aura Kay Gonzales ; Erwin Dizon ; Jamie Lynn Co
Philippine Journal of Internal Medicine 2025;63(3):109-113
INTRODUCTION
Most cancer-related deaths globally are caused by lung cancer. The diagnosis is typically made following the evaluation of respiratory symptoms such as chronic cough or incidental finding of pulmonary lesions such as nodules and mass. Cardiac metastasis occurs in 2-18% of lung cancers, but cardiac tamponade complicating malignant pericardial effusion is an extremely rare and life-threatening initial presentation of non-small cell lung carcinoma.
CASE REPORTA 59-year-old-male with a smoking history of 72 pack-year presented at the emergency room with severe dyspnea and was assessed to be in cardiac tamponade. The patient arrested for 16 minutes but returned to spontaneous circulation after 650mL of serosanguinous fluid was removed by pericardiocentesis. The work-up for infectious and immunologic causes was negative. Chest CT scan with contrast did not reveal any pulmonary mass. However, the pericardial fluid cytology immunohistochemical stains pointed to a primary lung adenocarcinoma. PET scan was requested which confirmed hypermetabolic focus in the left lung base. included patients admitted at East Avenue Medical Center for DFU. The primary endpoint was major amputation of the lower extremities. Data were analyzed using Receiver Operating Characteristic (ROC) analysis and logistic regression.
CONCLUSIONThis case showed an extremely rare situation where life-threatening cardiac tamponade was the initial presentation of non-small cell lung adenocarcinoma, which highlights the need for vigilance in atypical presentation. Comprehensive diagnostic approach, including PET scans and cytologic analysis, must be done when standard imaging is inconclusive.
Human ; Male ; Middle Aged: 45-64 Yrs Old ; Cardiac Tamponade ; Adenocarcinoma Of Lung
6.FCN3 Can Serve as A Potential Biomarker for Prognosis and Immunotherapy of Lung Squamous Cell Carcinoma.
Wei LI ; Lingling ZU ; Song XU
Chinese Journal of Lung Cancer 2025;28(2):114-130
BACKGROUND:
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Lung squamous cell carcinoma (LUSC) is an important pathological subtype of NSCLC. The complex immune escape mechanism limits the effectiveness of immunotherapy. Ficolin-3 (FCN3) is a crucial immunomodulatory molecule that regulates immune escape by remodeling the tumor microenvironment. However, the role of FCN3 in LUSC remains unclear. This study employed bioinformatics methods to analyze LUSC samples from The Cancer Genome Atlas (TCGA) database. The aim of this study was to explore the potential biological functions and prognostic significance of FCN3 in LUSC.
METHODS:
A pan-cancer analysis characterized the expression patterns and prognostic value of FCN3 across various cancer types. Simultaneously, the expression patterns of FCN3 in LUSC samples from the TCGA database and its relationship with prognosis were analyzed. The Nomogram model and somatic mutation analysis, differential expression analysis, correlation analysis, as well as Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were constructed to explore the potential mechanisms of FCN3. Additionally, immune infiltration analysis, immune escape score (TIDE), and correlation analysis of immune-related molecules were used to reveal the regulatory role of high FCN3 levels on immunity in LUSC. Furthermore, the correlation between FCN3 expression characteristics and drug sensitivity was evaluated. Finally, in vitro experiments verified the expression characteristics of FCN3 in LUSC.
RESULTS:
The expression level of FCN3 in LUSC tissues was significantly lower than that in normal tissues. Patients with high FCN3 expression in LUSC had a poorer prognosis compared to those with low expression. Different expression levels of FCN3 were associated with the abundance of immune cell infiltration and immune cell dysfunction. It was also linked to the expression of immune checkpoints, immune stimulatory molecules, major histocompatibility complex (MHC) class molecules, and chemotherapy drug sensitivity.
CONCLUSIONS
High expression of FCN3 in LUSC is associated with poor prognosis and is linked to immune cell infiltration, immune-related pathways, and immune-related molecules. FCN3 may be a potential prognostic marker and a new target for immunotherapy in LUSC.
Humans
;
Lung Neoplasms/immunology*
;
Immunotherapy
;
Biomarkers, Tumor/metabolism*
;
Prognosis
;
Lectins/metabolism*
;
Carcinoma, Squamous Cell/immunology*
;
Ficolins
;
Gene Expression Regulation, Neoplastic
7.Research Progress on Imaging Diagnosis of Non-small Cell Lung Cancer Which Invades Pleura or Chest Wall.
Chinese Journal of Lung Cancer 2025;28(2):131-137
Accurate staging is the fundamental basis for the treatment and prognosis of non-small cell lung cancer (NSCLC), and whether the tumor involves the pleura or chest wall is a critical aspect in assessing the staging of peripheral lung cancer. Imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), ultrasound (US) and positron emission tomography (PET) are widely used to determine pleural invasion in NSCLC. There has been an increasing number of studies evaluating whether NSCLC invades the pleura and the extent of such invasion. This article provides a review of the staging and the imaging diagnostic criteria of pleural invasion, aiming to offer references for peers in the precise diagnosis of pleural or chest wall invasion.
.
Humans
;
Carcinoma, Non-Small-Cell Lung/diagnosis*
;
Lung Neoplasms/diagnosis*
;
Thoracic Wall/diagnostic imaging*
;
Pleura/diagnostic imaging*
;
Neoplasm Invasiveness
;
Tomography, X-Ray Computed
8.Research Progress on Molecular Subtypes and Precision Therapy of Pulmonary Large Cell Neuroendocrine Carcinoma.
Chinese Journal of Lung Cancer 2025;28(2):146-154
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine tumor with unique characteristics, and its treatment regimens are primarily derived from those for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In recent years, the incidence rate has been on the rise, and the prognosis are affected by the interaction of multiple factors such as individual, clinical stage and treatment mode, and the heterogeneity is significant. In the study of molecular subtypes, multiple subgroups were divided according to key gene mutations such as RB1 and TP53, and genomic subtypes were associated with survival, chemotherapy response, and efficacy of precision therapy. Targeted therapy excavates multiple targets, and the efficacy of drugs is different. Immunotherapy has made remarkable progress, and immune checkpoint inhibitors (ICIs) have been effective in all stages of chemotherapy alone or in combination with chemotherapy or radiation therapy, but there is a risk of hyperprogressive diseases, and accurate prognostic markers need to be explored urgently. This review reviews the latest research progress in the study of molecular subtypes and precision therapies such as targeted therapy and immunotherapy of pulmonary LCNEC, and points out that pulmonary LCNEC treatment will develop in the direction of precision and individualization in the future.
.
Humans
;
Lung Neoplasms/drug therapy*
;
Carcinoma, Neuroendocrine/drug therapy*
;
Precision Medicine
;
Immunotherapy
;
Carcinoma, Large Cell/drug therapy*
9.Epithelial-mesenchymal Transition: Biological Basis and Clinical Prospects of Lung Cancer Invasion, Metastasis, and Drug Resistance.
Hengxing SUN ; Mengting XIONG ; Shuanshuan XIE ; Jing WEN
Chinese Journal of Lung Cancer 2025;28(2):155-164
Lung cancer is the leading cause of cancer-related deaths worldwide, characterized by high incidence and mortality rates. The primary reasons for treatment failure in lung cancer patients are tumor invasion and drug resistance, particularly resistance to chemotherapeutic agents and epidermal growth factor receptor (EGFR) mutant targeted therapy, which considerably undermine the therapeutic outcomes for those with advanced lung cancer. Epithelial-mesenchymal transition (EMT) serves as a crucial biological process closely associated with physiological or pathological processes such as tissue embryogenesis, organogenesis, wound repair, and tumor invasion. Numerous studies have indicated that EMT, mediated through various signaling pathways, plays a pivotal role in the initiation, progression, and metastasis of lung cancer, while it is also closely associated with drug resistance in lung cancer cells. Therefore, research focusing on the molecular mechanisms and pathophysiology related to EMT can contribute to reversing drug resistance in drug treatment for lung cancer, thereby improving prognosis. This article reviews the progress in research on EMT in the invasion, metastasis, and drug resistance of lung cancer based on relevant domestic and international literature.
Humans
;
Epithelial-Mesenchymal Transition/drug effects*
;
Drug Resistance, Neoplasm
;
Lung Neoplasms/physiopathology*
;
Neoplasm Metastasis
;
Neoplasm Invasiveness
;
Animals
;
Antineoplastic Agents/therapeutic use*
10.ARID1B Gene Deletion Promotes the Proliferation, Migration and Invasion of NSCLC Cells.
Chinese Journal of Lung Cancer 2025;28(3):165-175
BACKGROUND:
Abnormalities of the switch/sucrose nonfermentable (SWI/SNF) chromatin-remodeling complex are closely related to various cancers, and ARID1B (AT-rich interaction domain 1B) is one of the core subunits of the SWI/SNF complex. Mutations or copy number deletions of the ARID1B gene are associated with impaired DNA damage response and altered chromatin accessibility. However, whether ARID1B deficiency affects the proliferation, migration and invasion abilities of non-small cell lung cancer (NSCLC) cells and its molecular mechanisms remain poorly understood. This study aims to reveal the regulatory role of ARID1B gene deletion on the malignant phenotype of NSCLC cells and its molecular mechanism.
METHODS:
Online databases were used to analyze the relationship between ARID1B and the prognosis of patients with lung cancer, and the expression levels of ARID1B in lung cancer tissues. The CRISPR/Cas9 (clustered regularly interspaced short palindromic repeat) technology was employed to construct stable ARID1B gene knockout (KO) cell lines. The plate colony formation assay was used to detect cell proliferation, and the Transwell cell migration and invasion assays were used to detect changes in cell migration ability. RNA-Seq was utilized for the expression and enrichment analysis of differentially expressed genes. Western blot (WB) was used to verify the knockout effect of the ARID1B gene and to detect the expression changes of epithelial-mesenchymal transition (EMT) markers and mitogen-activated protein kinases (MAPK) signaling pathway-related proteins. Nude mouse tumor models were constructed and the tumorigenic abilities of control and ARID1B-deficient cells were compared.
RESULTS:
Patients with low ARID1B expression have poor overall survival. ARID1B is differentially expressed in lung cancer and normal tissues, and its expression level being lower in cancer cells. ARID1B-deficient cells had significantly enhanced in vitro proliferation, migration and invasion abilities. In animal experiments, the tumor formation speed of ARID1B gene deficient cells was significantly accelerated. Enrichment analysis of RNA-Seq results revealed that the differentially expressed genes were mainly enriched in MAPK, phosphoinositide 3-kinase-protein kinase B (PI3K/Akt) and other signaling pathways. WB experiments demonstrated that the expressions of E-cadherin, N-cadherin and Vimentin changed in ARID1B gene deficient cells, and the expressions of MAPK and p-MAPK was increased.
CONCLUSIONS
The A549-ARID1B KO and PC9-ARID1B KO cell lines were successfully established. The ARID1B-deficient cell lines demonstrated high migration, invasion and proliferation potential at both in vitro and in vivo biological behavior levels and at the transcriptome sequencing level. The changes in the expression of EMT markers and the activation of the MAPK signaling pathway suggest possible metastasis mechanisms of ARID1B-deficient NSCLC.
Humans
;
Cell Proliferation/genetics*
;
Cell Movement/genetics*
;
Lung Neoplasms/metabolism*
;
Animals
;
Carcinoma, Non-Small-Cell Lung/physiopathology*
;
Transcription Factors/metabolism*
;
Neoplasm Invasiveness
;
Mice
;
DNA-Binding Proteins/metabolism*
;
Gene Deletion
;
Cell Line, Tumor
;
Epithelial-Mesenchymal Transition
;
Mice, Nude
;
Gene Expression Regulation, Neoplastic


Result Analysis
Print
Save
E-mail